다우존스 지수

실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Allos Therapeutics, Inc. (MM) (ALTH)
Allos Therapeutics, Inc. (MM) (ALTH) 뉴스

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ALTH

<< 이전 15 16 17 18 19 20 21 22 23 24 25 26 27 28 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2007/04/19	21:30	PR Newswire (US)	Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European Commission	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2007/03/20	21:00	PR Newswire (US)	Allos Therapeutics Appoints Pablo J. Cagnoni, M.D. as Chief Medical Officer	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2007/03/05	21:00	PR Newswire (US)	Allos Therapeutics Reports Fourth Quarter and 2006 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2007/02/27	22:00	PR Newswire (US)	Allos Therapeutics to Report 2006 Fourth Quarter Financial Results on Monday, March 5	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2007/02/13	22:00	PR Newswire (US)	Allos Therapeutics to Present at Upcoming Investor Conferences	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2007/02/03	01:01	PR Newswire (US)	Allos Therapeutics Announces Closing of Common Stock Offering	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2007/01/30	20:00	PR Newswire (US)	Allos Therapeutics Announces Pricing of Underwritten Offering of 9,000,000 Shares of Common Stock	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2007/01/09	05:19	PR Newswire (US)	Allos Therapeutics to Present at the 2007 JP Morgan Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2007/01/08	21:05	PR Newswire (US)	Allos Therapeutics Appoints William R. Ringo to Its Board of Directors	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2007/01/08	21:00	PR Newswire (US)	Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 Trial of Its Novel Antifolate PDX in Patien	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/12/12	01:46	PR Newswire (US)	Results Reported at the American Society of Hematology Annual Meeting Affirm Impressive Activity of Allos Therapeutics' Novel An	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/11/20	22:00	PR Newswire (US)	Allos Therapeutics Added to NASDAQ Biotech Index	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/11/10	22:15	PR Newswire (US)	Updated Safety Analysis of Allos Therapeutics Phase 1/2 Study of PDX in Patients With Aggressive Lymphomas Demonstrates Decrease	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/11/10	03:56	PR Newswire (US)	Allos Therapeutics Announces Presentation of Updated Results From Phase 1/2 Trial of PDX in Patients With Aggressive Lymphomas a	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/11/07	02:00	PR Newswire (US)	Updated Analysis Demonstrates Long-Term Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Receiving Sequential Chemor	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/11/03	21:30	PR Newswire (US)	Allos Therapeutics Reports Third Quarter 2006 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/11/02	06:00	PR Newswire (US)	Allos Therapeutics to Announce 2006 Third Quarter Financial Results on Friday, November 3	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/11/01	02:30	PR Newswire (US)	Allos Therapeutics Announces Presentations on EFAPROXYN(TM) and PDX at Upcoming Scientific Conferences	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/10/23	20:29	PR Newswire (US)	Allos Therapeutics Announces ENRICH Trial Update	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/10/03	22:00	PR Newswire (US)	Allos Therapeutics Receives FDA Fast Track Designation for PDX for the Treatment of T-cell Lymphoma	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/08/29	21:30	PR Newswire (US)	Allos Therapeutics to Present at Upcoming Investor Conferences	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/08/29	21:00	PR Newswire (US)	Allos Therapeutics Initiates Pivotal Phase 2 Study of PDX in Patients With Peripheral T-cell Lymphoma	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/08/28	21:00	PR Newswire (US)	Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Study of EFAPROXYN(TM) in Women with Brain Metastases Origin	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/08/07	21:00	PR Newswire (US)	Allos Therapeutics Reports Second Quarter 2006 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/08/02	21:30	PR Newswire (US)	Allos Therapeutics Receives Special Protocol Assessment for Pivotal Phase 2 Study of the Company's Novel Antifolate PDX in Pati	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/07/26	22:00	PR Newswire (US)	FDA Grants Orphan Drug Designation to Allos Therapeutics' Novel Antifolate PDX for the Treatment of T-cell Lymphoma	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/06/14	21:00	PR Newswire (US)	Retrospective Analysis of Allos Therapeutics' Phase 3 REACH Study Finds Positive Correlation between Patient Outcomes and EFAPR	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/06/13	21:12	PR Newswire (US)	Allos Therapeutics Files Shelf Registration Statement	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/06/07	22:00	PR Newswire (US)	Allos Therapeutics to Present at the 2006 Needham & Company Biotechnology Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
2006/06/06	08:07	PR Newswire (US)	Allos Therapeutics Appoints James V. Caruso as Chief Commercial Officer	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)

검색 관련기사 보기:NASDAQ:ALTH

<< 이전 15 16 17 18 19 20 21 22 23 24 25 26 27 28 다음 >>

Intesa Sanpaolo

Bremer Lagerhaus Gesells...

Tchaikapharma High Quali...

State Auto Financial

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관